ClinicalTrials.gg
Active, not recruitingNCT07931118Updated Nov 12, 2026

Lower Urinary Tract Dysfunction and Training Intensity in Female Student Athletes

An observational study in Lower Urinary Tract Dysfunction, Lower Urinary Tract Symptoms (LUTS) and Female Athletes, sponsored by Istanbul Galata University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Istanbul Galata University · Observational

Updated Nov 12, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
120
Ages
18 Years to 25 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 45 studies in Lower Urinary Tract Symptoms with a site in Turkey — 13 open to participants now, 14 under way, none of them phase 3. Lower Urinary Tract Symptoms · Turkey.

Planned enrollment
12th of 24
120 · median 110
Started
2026
with 9 others
Observational
24 of 45
9 open now
Primary completion
2026-11
later than 4 of 13 live
Registered
45th of 45
by date

Among the 45 studies in Lower Urinary Tract Symptoms with a site in Turkey, this one is the 12th largest by planned enrollment of the 24 observational ones that give a count, is one of 10 that started in 2026, is one of 24 observational ones, reaches primary completion later than 4 of the 13 other live ones, and was the 45th registered.

Lower Urinary Tract Symptoms

417 studies on the registry are indexed under Lower Urinary Tract Symptoms; 110 are open to participants now.

Browse Lower Urinary Tract Symptoms studies →

Open to participants now

13 of the 45 studies in Lower Urinary Tract Symptoms with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 59 Lower Urinary Tract Symptoms studies recruiting now, 39 (66%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 25 Years · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Lower Urinary Tract Symptoms with a site in Turkey, or all of them as a file.
02

Study summary

The goal of this observational, cross-sectional study is to examine the relationship between training intensity and awareness of lower urinary tract dysfunction (LUTD) among female student athletes aged 18-25 years who are actively engaged in gymnastics, volleyball, football, or basketball.

The main questions it aims to answer are:

  • What is the prevalence and severity of lower urinary tract dysfunction among female university athletes?
  • Is there a relationship between LUTD symptoms (as measured by UDI-6 and ICIQ-SF) and years of sports participation, training load, weekly hours, or sport type?

Researchers will compare the four sport groups (gymnastics, volleyball, football, basketball) to determine whether training characteristics and sport-specific demands influence LUTD prevalence and symptom severity.

Participants will:

  • Read and sign an electronic informed consent form.
  • Complete an online questionnaire via Google Forms, including:

Urogenital Distress Inventory-6 (UDI-6)

International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) Contentment with Life Scale

Demographic and lifestyle questions (e.g., training duration, intensity, fluid intake, menstrual regularity, sleep, stress).

The study aims to contribute to early detection and prevention strategies for pelvic floor health issues in young female athletes.

03

Conditions studied

  • Lower Urinary Tract Dysfunction
  • Lower Urinary Tract Symptoms (LUTS)
  • Female Athletes
04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

Female university athletes aged 18-25 years who are actively training and competing in gymnastics, volleyball, football, or basketball at Marmara University and Istanbul Galata University in Türkiye. Participants must be healthy, without known pelvic pathology, and currently engaged in organized sports training.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female sex.
  • Age 18-25 years.
  • Currently enrolled as a university student.
  • Actively training in gymnastics, volleyball, football, or basketball for at least 1 year.
  • Participating in regular training at least 2 times per week.

Exclusion criteria

Exclusion Criteria:

  • History of pelvic surgery
  • Current pregnancy or childbirth within the past 6 months.
  • Known neurological disorders affecting bladder function
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • Gymnastics athletes

    Female athletes aged 18-25 actively training in gymnastics. (n=30)

  • Volleyball athletes

    Female athletes aged 18-25 actively training in volleyball. (n=30)

  • Football athletes

    Female athletes aged 18-25 actively training in football. (n=30)

  • Basketball athletes

    Female athletes aged 18-25 actively training in basketball. (n=30)

06

What researchers measure

Primary outcomes

  1. Urogenital Distress Inventory (UDI-6)

    self-administered Likert-type questionnaire designed to evaluate the presence and severity of lower urinary tract dysfunction symptoms.Total scores range from 0 to 18, and are converted into percentages for interpretation. Higher scores indicate more severe symptoms and a greater negative impact on quality of life.

    Time frame: Day 1 (Single assessment at one time point during participation)

  2. International Consultation on Incontinence Questionnaire- Short Form (ICIQ- SF)

    Used to assess the impact of urinary incontinence on quality of life and treatment need. It includes four items addressing the frequency of urinary incontinence, Amount of leakage, Overall impact on daily life and Self-diagnostic item. Scores range from 0 to 21, with higher scores indicating more severe symptoms and greater impairment of quality of life.

    Time frame: Day 1 (Single assessment at one time point during participation)

  3. Contentment with Life Assessment Scale (CLAS)

    The scale consists of 5 items rated on a 7-point Likert scale (1 = strongly disagree to 7 = strongly agree). Higher scores indicate greater life satisfaction.

    Time frame: Day 1 (Single assessment at one time point during participation)

Secondary outcomes

  1. Body Mass Index (BMI)

    Calculated as weight (kg) / height² (m²). Classified according to WHO standards.

    Time frame: Day 1 (Single assessment at one time point during participation)

  2. Demographic and training characteristics checklist

    Collected using a custom-designed questionnaire including: Demographic data (date of birth, academic department, year of study, body weight, height, sports branch, age of starting the sport) Training information (weekly frequency, duration, and intensity)

    Time frame: Day 1 (Single assessment at one time point during participation)

Other outcomes

  1. Competition participation and achievements checklist

    Type and level of competitions, national team status, awards within the past year

    Time frame: Day 1 (Single assessment at one time point during participation)

  2. Lifestyle and menstrual health variables

    Collected using self-report questions assessing daily activity level, sitting time, sleep duration and quality, fluid intake, menstrual regularity, and stress levels.

    Time frame: Day 1 (Single assessment at one time point during participation)

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Nov 2026, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 12, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Mar 20, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07931118
Lead sponsor
Istanbul Galata University
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Oct 1, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Mar 20, 2027 (estimated)
Last update
Nov 12, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion